Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice

被引:7
|
作者
Pinton, Piergiacomo Calzavara [1 ]
Licitra, Lisa [2 ]
Peris, Katia [3 ]
Santoro, Armando [4 ]
Ascierto, Paolo Antonio [5 ]
机构
[1] Univ & Spedali Civili, Dept Dermatol, Brescia, Italy
[2] Ist Nazl Tumori, Head & Neck Canc Unit, I-20133 Milan, Italy
[3] Univ Cattolica Sacro Cuore, Dept Dermatol, I-00168 Rome, Italy
[4] Ist Clin Humanitas IRCCS, Humanitas Canc Ctr, Rozzano, Italy
[5] Ist Nazl Tumori Fdn G Pascale, Melanoma Canc Immunotherapy & Innovat Therapies, Naples, Italy
关键词
adverse events; basal cell carcinoma; clinical practice; vismodegib; HEDGEHOG PATHWAY INHIBITOR; NEOADJUVANT;
D O I
10.2217/fon.15.20
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Basal cell carcinoma (BCC) is a frequent skin cancer which can cause substantial morbidity due to its location on the face, its frequency of relapse and its capacity to invade local tissues. The primary treatment of BCC usually involves surgery or radiotherapy. In patients who have exhausted surgical and radiotherapy options or with metastatic BCC, guidelines recommend the use of the Hedgehog pathway inhibitor vismodegib. This molecule is indicated for the treatment of adults with metastatic BCC, or with locally advanced BCC which has recurred following surgery or who are not eligible to surgery or radiation. This paper aims to provide suggestions on the optimal management of BCC patients treated with vismodegib in clinical practice, according to the large experience gained by a group of Italian dermatologists and oncologists. In particular, the focus of this paper will be on the monitoring of patients and the management of adverse events.
引用
收藏
页码:1429 / 1435
页数:7
相关论文
共 50 条
  • [31] Vismodegib treatment for recurrent basal cell carcinoma – a successful case report
    Ana Maria Lé
    Miguel Nogueira
    Alexandra Araújo
    Miguel Horta
    European Journal of Dermatology, 2023, 33 : 332 - 333
  • [32] Vismodegib for periocular and orbital basal cell carcinoma
    Wong, K. Y.
    Fife, K.
    Lear, J. T.
    Ali, F. R.
    Price, R. D.
    Durrani, A. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (03) : E59 - E60
  • [33] Vismodegib for Periocular and Orbital Basal Cell Carcinoma
    Gill, Harmeet S.
    Moscato, Eve E.
    Chang, Anne Lynn S.
    Soon, Seaver
    Silkiss, Rona Z.
    JAMA OPHTHALMOLOGY, 2013, 131 (12) : 1591 - 1594
  • [34] Vismodegib: A Review in Advanced Basal Cell Carcinoma
    James E. Frampton
    Nicole Basset-Séguin
    Drugs, 2018, 78 : 1145 - 1156
  • [35] Vismodegib: A Review in Advanced Basal Cell Carcinoma
    Frampton, James E.
    Basset-Seguin, Nicole
    DRUGS, 2018, 78 (11) : 1145 - 1156
  • [36] Drug holiday approach for Vismodegib treatment in patients with nevoid basal cell carcinoma syndrome: Three cases from real clinical practice
    Valenzuela-Onate, Cristian Alejandro
    Magdaleno-Tapial, Jorge
    Garcia-Legaz Martinez, Marta
    Perez-Pastor, Gemma
    Sanchez Carazo, Jose Luis
    DERMATOLOGIC THERAPY, 2020, 33 (04)
  • [37] Vismodegib for periocular and orbital basal cell carcinoma
    Wong, K. Y.
    Fife, K.
    Lear, J. T.
    Ali, F. R.
    Price, R. D.
    Durrani, A. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 : 47 - 47
  • [38] Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib
    Iarrobino, Amy
    Messina, Jane L.
    Kudchadkar, Ragini
    Sondak, Vernon K.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 69 (01) : E33 - E34
  • [39] Vismodegib: the Proof of Concept in Basal Cell Carcinoma
    Berrada, Narjiss
    Lkhoyali, Siham
    Mrabti, Hind
    Errihani, Hassan
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2014, 8 : 77 - 80
  • [40] Vismodegib Therapy for Periocular Basal Cell Carcinoma
    Keser, M.
    Green, S.
    Dulz, S.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2017, 234 (01) : 64 - 69